SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

ABCL575

ABCL·AbCellera Biologics Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1
Time to market
Not applicable; development has been paused with no timeline for resumption.
Why 2/10
ABCL575 has been shelved (development paused) per AbCellera's Q3 2026 earnings call on November 9, 2026. With no active clinical trial or upcoming hard-dated catalyst, the impact score is low.
Actionable Insight NEUTRAL

AbCellera announced on its Q3 2026 earnings call (November 9, 2026) that it is shelving further development of ABCL575 for now, while prioritizing ABCL635 (hot flash treatment) for late-stage development. Investors should watch whether AbCellera ever resumes ABCL575 development or partners it out, but near-term attention is on ABCL635's Phase 2-to-Phase 3 transition in 2027.

Price Chart

Loading chart...

Executive Summary

ABCL575 is an anti-OX40L monoclonal antibody that AbCellera was developing for moderate-to-severe atopic dermatitis. It showed promising preclinical data and entered Phase 1 clinical trials in Canada in mid-2025. However, on November 9, 2026, AbCellera announced it is shelving further development of ABCL575 to focus resources on its lead asset ABCL635 (a hot flash treatment), which recently reported positive Phase 2 results. With no active development or upcoming catalysts, ABCL575 is currently a parked program.

How It Works

ABCL575 is an antibody designed to block OX40L, a protein involved in activating immune cells that drive inflammation. By blocking OX40L, the drug aims to reduce the inflammatory response underlying atopic dermatitis (eczema). It is engineered to last longer in the body (half-life extended) and to avoid triggering unwanted immune cell activity (Fc-silenced).

Trial Status

ABCL575 completed first-in-human dosing in a Phase 1 trial (started Q3 2025, first participants dosed August 2025). However, per AbCellera's Q3 2026 earnings call on November 9, 2026, the company has shelved further development of this antibody candidate for now, prioritizing its other pipeline asset ABCL635 instead.

The Two-Sided Case

▲ Bull Case3
OX40L is a validated target in atopic dermatitis; approved drugs targeting the OX40 pathway (like amlitelimab) have shown efficacy, suggesting the mechanism is sound.
Preclinical data presented at the 2025 SID Annual Meeting showed potent inhibition of inflammatory pathways and favorable in vivo activity.
AbCellera has a strong balance sheet (roughly $700M+ in liquidity per recent reports) and could potentially resume or partner ABCL575 in the future if strategic priorities shift.
▼ Bear Case4
AbCellera has shelved ABCL575 development entirely as of November 2026, with no timeline for resumption.
The atopic dermatitis treatment market is highly competitive, with multiple approved biologics (Dupixent, Adbry, etc.) and other OX40-targeting drugs in development.
ABCL575 was only in Phase 1; it had not yet generated any efficacy data in humans, so its therapeutic profile remains unproven.
AbCellera is prioritizing ABCL635 (hot flashes), which may keep ABCL575 on the back burner indefinitely.

Upcoming Catalysts

  • No upcoming catalysts: ABCL575 development has been shelved per the Q3 2026 earnings call.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbCellera Biologics Inc. 8-K ABCL ·Originating report

Sources · 5

Hover a chip for the title
1 nasdaq.com2 nasdaq.com3 nasdaq.com4 seekingalpha.com5 msn.com